Immutep Reports P-I Trial (INSIGHT-003) Results of Triple Combination Therapy as 1L Treatment of Non-Small Cell Lung Cancer


The P-I trial (INSIGHT-003) evaluating eftilagimod alpha (soluble LAG-3 protein & MHC Class II agonist) + SoC anti-PD-1 therapy & doublet CT. The trial was conducted by the Frankfurt Institute of Clinical Cancer Research IKF
The results showed that the triple combination therapy was well-tolerated & showed promising initial efficacy signals, ORR (67%), DCR (91%), 81% had a PD-L1 TPS of <50% who are less responsive to anti-PD-1 based therapy vs PD-L1 high expressing patients & 65% response rate in patients with PD-L1 TPS <50%
Additional results from the P-I trial are expected to be presented at a major medical conference in H2’23. The therapy received FTD in 1L HNSCC & NSCLC from the US FDA

Ref: Globenewswire | Image: Immutep

Related News:- Immutep Enters into a Clinical Trial Collaboration with Merck KGaA and Pfizer to Evaluate Eftilagimod Alpha (Efti) for Urothelial Cancer

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at